AIM
NYSE MKT HealthcareAIM ImmunoTech Inc. Common Stock
Biotechnology
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
�� 市场数据
| 价格 | $0.83 |
|---|---|
| 成交量 | 24,613,647 |
| 市值 | 12.04M |
| 贝塔系数 | 1.240 |
| RSI（14日） | 72.7 超买 |
| 200日均线 | $1.38 |
| 50日均线 | $0.51 |
| 52周最高 | $19.74 |
| 52周最低 | $0.21 |
| Forward P/E | -1.59 |
| Price / Book | -0.26 |
🎯 投资策略评分
AIM 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (93/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 💰 Dividend Daddy (20/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 AIM in your text
粘贴任何文章、记录或帖子 — 工具将提取 AIM 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.